To defend its position in the anti-obesity market, Novo Nordisk has responded on multiple fronts, cutting prices on existing Wegovy doses in India by up to 37% in November 2025, partnering with Emcure to bring another semaglutide brand to the Indian market, and now moving to a higher-dose formulation that generics cannot replicate immediately
The production of ROS and free radicals exacerbates inflammation and hyperplasia of keratinocyte cells [8]
Mme lorsque les chiffres defficacit sont impressionnants, la russite dpend de trois points : Une indication bien pose IMC, comorbidits (apne du sommeil, HTA, diabte, dyslipidmie, statose hpatique), traitements en cours, histoire pondrale, risques
This is the DermaVue clinical protocol developed across several thousand GLP-1 patients